In this sense, drugs as sodium-glucose cotransporter 2 inhibitors, which have demonstrated a clear reduction in HF events in patients with diabetes [25,26] and with HF with or without diabetes and independently of reduced or preserved ejection fraction [27,28,29,30], which were not available at the inclusion in our study, would have probably resulted in a significant impact in the reduction in events in a population similar to that of the present study. Here, SLC5A2 is linked to diabetes mellitus.